Camu-camu could become an adjuvant therapy to assist anti-VEGF therapy in patients with abnormal neovascularization and subsequent RPE atrophy in an era of rising expectations regarding functional foods and superfoods. The gene discussed is VEGFA; the disease is Atrophy.